

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-33497

**Amicus Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of  
Incorporation or Organization)

71-0869350

(I.R.S. Employer  
Identification Number)

47 Hulfish Street, Princeton, NJ  
(Address of Principal Executive Offices)

08542  
(Zip Code)

(609) 662-2000

(Registrant's Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	FOLD	NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares outstanding of the registrant's common stock, \$0.01 par value per share, as of October 25, 2024 was 298,805,773 shares.

AMICUS THERAPEUTICS, INC.

Form 10-Q for the Quarterly Period Ended September 30, 2024

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	<b><u>3</u></b>
Item 1. <a href="#"><u>Consolidated Financial Statements and Notes (unaudited)</u></a>	<a href="#"><u>3</u></a>
<a href="#"><u>Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023</u></a>	<a href="#"><u>3</u></a>
<a href="#"><u>Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023</u></a>	<a href="#"><u>4</u></a>
<a href="#"><u>Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023</u></a>	<a href="#"><u>5</u></a>
<a href="#"><u>Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023</u></a>	<a href="#"><u>6</u></a>
<a href="#"><u>Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023</u></a>	<a href="#"><u>8</u></a>
<a href="#"><u>Notes to Consolidated Financial Statements</u></a>	<a href="#"><u>9</u></a>
Item 2. <a href="#"><u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u></a>	<a href="#"><u>19</u></a>
Item 3. <a href="#"><u>Quantitative and Qualitative Disclosures about Market Risk</u></a>	<a href="#"><u>27</u></a>
Item 4. <a href="#"><u>Controls and Procedures</u></a>	<a href="#"><u>27</u></a>
<b><u>PART II. OTHER INFORMATION</u></b>	<b><u>27</u></b>
Item 1. <a href="#"><u>Legal Proceedings</u></a>	<a href="#"><u>27</u></a>
Item 1A. <a href="#"><u>Risk Factors</u></a>	<a href="#"><u>27</u></a>
Item 2. <a href="#"><u>Unregistered Sales of Equity Securities and Use of Proceeds</u></a>	<a href="#"><u>27</u></a>
Item 3. <a href="#"><u>Defaults Upon Senior Securities</u></a>	<a href="#"><u>28</u></a>
Item 4. <a href="#"><u>Mine Safety Disclosures</u></a>	<a href="#"><u>28</u></a>
Item 5. <a href="#"><u>Other Information</u></a>	<a href="#"><u>28</u></a>
Item 6. <a href="#"><u>Exhibits</u></a>	<a href="#"><u>30</u></a>
<b><u>SIGNATURES</u></b>	<b><u>31</u></b>

## SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "might," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.

We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:

- the scope, progress, results and costs of clinical trials for our drug candidates;
- the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pombiliti<sup>®</sup> (also referred to as "ATB200" or "cipaglucosidase alfa");
- the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize such therapies;
- the costs, timing, and outcome of regulatory review of our product candidates;
- any changes in regulatory standards relating to the review of our product candidates;
- any changes in laws, rules or regulations affecting our ability to manufacture, transport, test, develop, or commercialize our products, including Galafold<sup>®</sup>, Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>, or our product candidates;
- the costs of commercialization activities, including product marketing, sales, and distribution;
- the emergence of competing technologies and other adverse market developments;
- the estimates regarding the potential market opportunity for our products and product candidates;
- our ability to successfully commercialize Galafold<sup>®</sup> (also referred to as "migalastat HCl");
- our ability to successfully commercialize Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> (together, also referred to as "AT-GAA") in the E.U., U.K., U.S., Switzerland and elsewhere, if regulatory applications are approved;
- our ability to manufacture or supply sufficient clinical or commercial products, including Galafold<sup>®</sup> and Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>;
- our ability to obtain reimbursement for Galafold<sup>®</sup> and Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>;
- our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold<sup>®</sup> and Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>;
- our ability to obtain market acceptance of Galafold<sup>®</sup> and Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>, or any other product developed or acquired that has received regulatory approval;
- the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;
- the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others, including Hatch-Waxman litigation;
- the extent to which we acquire or invest in businesses, products, and technologies;
- our ability to successfully integrate acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;
- our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other economic benefits from any such collaborators;

- the costs associated with, and our ability to comply with, emerging environmental, social and governance standards, including climate reporting requirements at the local, state and national levels;
- our ability to successfully protect our information technology systems and maintain our global operations and supply chain without interruption;
- our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;
- fluctuations in foreign currency exchange rates; and
- changes in accounting standards.

In light of these risks and uncertainties, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in Part I Item 1A — Risk Factors of the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Those factors and the other risk factors described herein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future collaborations, alliances, business combinations, partnerships, strategic out-licensing of certain assets, the acquisition of preclinical-stage, clinical-stage, marketed products or platform technologies or other investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.

You should read this Quarterly Report on Form 10-Q in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (including the documents incorporated by reference therein) completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.

**PART I. FINANCIAL INFORMATION**

**ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (UNAUDITED)**

**Amicus Therapeutics, Inc.**  
**Consolidated Balance Sheets**  
*(Unaudited)*  
**(in thousands, except share and per share amounts)**

	September 30, 2024	December 31, 2023
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 233,647	\$ 246,994
Investments in marketable securities	16,110	39,206
Accounts receivable	98,073	87,632
Inventories	115,338	59,696
Prepaid expenses and other current assets	35,306	49,533
Total current assets	498,474	483,061
Operating lease right-of-use assets, net	23,144	26,312
Property and equipment, less accumulated depreciation of \$29,324 and \$25,429 at September 30, 2024 and December 31, 2023, respectively	30,438	31,667
Intangible assets, less accumulated amortization of \$4,974 and \$2,510 at September 30, 2024 and December 31, 2023, respectively	18,026	20,490
Goodwill	197,797	197,797
Other non-current assets	18,678	18,553
<b>Total Assets</b>	<b>\$ 786,557</b>	<b>\$ 777,880</b>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 13,481	\$ 15,120
Accrued expenses and other current liabilities	136,116	144,245
Operating lease liabilities	8,541	8,324
Total current liabilities	158,138	167,689
Long-term debt	389,494	387,858
Operating lease liabilities	46,623	48,877
Other non-current liabilities	13,477	13,282
Total liabilities	607,732	617,706
Commitments and contingencies		
Stockholders' equity:		
Common stock, \$0.01 par value, 500,000,000 shares authorized, 298,691,094 and 293,594,209 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	2,942	2,918
Additional paid-in capital	2,905,760	2,836,018
Accumulated other comprehensive income (loss):		
Foreign currency translation adjustment	25,159	5,429
Unrealized loss on available-for-sale securities	(188)	(188)
Warrants	71	71
Accumulated deficit	(2,754,919)	(2,684,074)
Total stockholders' equity	178,825	160,174
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 786,557</b>	<b>\$ 777,880</b>

*See accompanying Notes to Consolidated Financial Statements*

**Amicus Therapeutics, Inc.**  
**Consolidated Statements of Operations**  
*(Unaudited)*  
(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net product sales	\$ 141,517	\$ 103,501	\$ 378,589	\$ 284,274
Cost of goods sold	13,279	9,946	38,107	26,002
Gross profit	128,238	93,555	340,482	258,272
Operating expenses:				
Research and development	26,160	40,704	79,172	117,352
Selling, general, and administrative	75,106	65,651	236,711	205,031
Changes in fair value of contingent consideration payable	—	1,995	—	2,583
Restructuring charges	3,143	—	9,188	—
Loss on impairment of assets	—	—	—	1,134
Depreciation and amortization	2,170	2,228	6,506	5,691
Total operating expenses	106,579	110,578	331,577	331,791
Income (loss) from operations	21,659	(17,023)	8,905	(73,519)
Other expense:				
Interest income	1,081	1,471	3,991	5,407
Interest expense	(12,692)	(12,986)	(37,640)	(37,322)
Other (expense) income	(3,263)	3,833	(11,946)	(13,007)
Income (loss) before income tax	6,785	(24,705)	(36,690)	(118,441)
Income tax (expense) benefit	(13,514)	3,128	(34,155)	700
<b>Net loss attributable to common stockholders</b>	<b>\$ (6,729)</b>	<b>\$ (21,577)</b>	<b>\$ (70,845)</b>	<b>\$ (117,741)</b>
Net loss attributable to common stockholders per common share — basic and diluted	\$ (0.02)	\$ (0.07)	\$ (0.23)	\$ (0.40)
Weighted-average common shares outstanding — basic and diluted	304,690,596	295,759,435	303,792,479	293,314,167

*See accompanying Notes to Consolidated Financial Statements*

**Amicus Therapeutics, Inc.**  
**Consolidated Statements of Comprehensive Income (Loss)**  
*(Unaudited)*  
(in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net loss	\$ (6,729)	\$ (21,577)	\$ (70,845)	\$ (117,741)
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustment	16,168	(10,910)	19,730	5,416
Unrealized gain (loss) on available-for-sale securities	9	(18)	—	(79)
Other comprehensive income (loss)	<u>16,177</u>	<u>(10,928)</u>	<u>19,730</u>	<u>5,337</u>
Comprehensive income (loss)	<u>\$ 9,448</u>	<u>\$ (32,505)</u>	<u>\$ (51,115)</u>	<u>\$ (112,404)</u>

*See accompanying Notes to Consolidated Financial Statements*

**Amicus Therapeutics, Inc.**  
**Consolidated Statements of Changes in Stockholders' Equity**  
*(Unaudited)*  
(in thousands, except share amounts)

**Three Months Ended September 30, 2024**

	Common Stock		Additional Paid-In Capital	Warrants	Other Comprehensive Income	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount					
Balance at June 30, 2024	296,428,877	\$ 2,923	\$ 2,868,925	\$ 71	\$ 8,794	\$ (2,748,190)	\$ 132,523
Stock options exercised, net	215,653	2	1,803	—	—	—	1,805
Vesting of restricted stock units, net of taxes	354,273	—	(2,792)	—	—	—	(2,792)
Stock-based compensation	—	—	18,688	—	—	—	18,688
Issuance of shares in connection with at-the-market offering, net of issuance costs	1,692,291	17	19,136	—	—	—	19,153
Unrealized gain on available-for-sale securities	—	—	—	—	9	—	9
Foreign currency translation adjustment	—	—	—	—	16,168	—	16,168
Net loss	—	—	—	—	—	(6,729)	(6,729)
Balance at September 30, 2024	298,691,094	\$ 2,942	\$ 2,905,760	\$ 71	\$ 24,971	\$ (2,754,919)	\$ 178,825

**Nine Months Ended September 30, 2024**

	Common Stock		Additional Paid-In Capital	Warrants	Other Comprehensive Income	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount					
Balance at December 31, 2023	293,594,209	\$ 2,918	\$ 2,836,018	\$ 71	\$ 5,241	\$ (2,684,074)	\$ 160,174
Stock options exercised, net	796,202	7	6,115	—	—	—	6,122
Vesting of restricted stock units, net of taxes	2,608,392	—	(21,197)	—	—	—	(21,197)
Stock-based compensation	—	—	65,688	—	—	—	65,688
Issuance of shares in connection with at-the-market offering, net of issuance costs	1,692,291	17	19,136	—	—	—	19,153
Foreign currency translation adjustment	—	—	—	—	19,730	—	19,730
Net loss	—	—	—	—	—	(70,845)	(70,845)
Balance at September 30, 2024	298,691,094	\$ 2,942	\$ 2,905,760	\$ 71	\$ 24,971	\$ (2,754,919)	\$ 178,825

**Three Months Ended September 30, 2023**

	Common Stock		Additional Paid-In Capital	Warrants	Other Comprehensive Loss	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount					
Balance at June 30, 2023	286,992,923	\$ 2,856	\$ 2,733,148	\$ 71	\$ 4,160	\$ (2,628,654)	\$ 111,581
Stock options exercised, net	372,467	4	3,438	—	—	—	3,442
Vesting of restricted stock units, net of taxes	299,297	—	(2,347)	—	—	—	(2,347)
Stock-based compensation	—	—	16,511	—	—	—	16,511
Issuance of shares in connection with at-the-market offering, net of issuance costs	3,002,354	30	36,525	—	—	—	36,555
Unrealized gain on available-for-sale securities	—	—	—	—	(18)	—	(18)
Foreign currency translation adjustment	—	—	—	—	(10,910)	—	(10,910)
Net loss	—	—	—	—	—	(21,577)	(21,577)
Balance at September 30, 2023	290,667,041	\$ 2,890	\$ 2,787,275	\$ 71	\$ (6,768)	\$ (2,650,231)	\$ 133,237

**Nine Months Ended September 30, 2023**

	Common Stock		Additional Paid-In Capital	Warrants	Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount					
Balance at December 31, 2022	281,108,273	\$ 2,815	\$ 2,664,744	\$ 83	\$ (12,105)	\$ (2,532,490)	\$ 123,047
Stock options exercised, net	1,025,684	11	7,836	—	—	—	7,847
Vesting of restricted stock units, net of taxes	2,068,048	—	(16,355)	—	—	—	(16,355)
Stock-based compensation	—	—	67,982	—	—	—	67,982
Warrants exercised	1,220,100	12	12	(12)	—	—	12
Issuance of shares in connection with at-the-market offering, net of issuance costs	5,244,936	52	63,056	—	—	—	63,108
Unrealized loss on available-for-sale securities	—	—	—	—	(79)	—	(79)
Foreign currency translation adjustment	—	—	—	—	5,416	—	5,416
Net loss	—	—	—	—	—	(117,741)	(117,741)
Balance at September 30, 2023	290,667,041	\$ 2,890	\$ 2,787,275	\$ 71	\$ (6,768)	\$ (2,650,231)	\$ 133,237

*See accompanying Notes to Consolidated Financial Statements*

**Amicus Therapeutics, Inc.**  
**Consolidated Statements of Cash Flows**  
*(Unaudited)*  
(in thousands)

	Nine Months Ended September 30,	
	2024	2023
<b>Operating activities</b>		
Net loss	\$ (70,845)	\$ (117,741)
Adjustments to reconcile net loss to net cash used in operating activities:		
Amortization of debt discount and deferred financing	1,665	2,080
Depreciation and amortization	6,506	5,691
Stock-based compensation	65,688	67,982
Non-cash changes in the fair value of contingent consideration payable	—	2,583
Foreign currency remeasurement loss	15,167	18,121
Deferred taxes	—	(4,939)
Other	7,048	2,360
Changes in operating assets and liabilities:		
Accounts receivable	(9,090)	(8,614)
Inventories	(61,632)	(42,233)
Prepaid expenses and other current assets	28,216	(26,010)
Accounts payable, accrued expenses, and other current liabilities	(11,483)	41,101
Other non-current assets and liabilities	(1,215)	(4,993)
Payment of contingent consideration	—	(7,937)
Net cash used in operating activities	\$ (29,975)	\$ (72,549)
<b>Investing activities</b>		
Sale and redemption of marketable securities	101,875	180,828
Purchases of marketable securities	(78,778)	(53,098)
Capital expenditures	(3,265)	(5,709)
Net cash provided by investing activities	\$ 19,832	\$ 122,021
<b>Financing activities</b>		
Payment of finance leases	(54)	(82)
Withholding taxes paid on vested restricted stock units	(21,197)	(16,355)
Proceeds from stock options exercised, net	6,122	7,847
Proceeds from warrants exercised, net	—	12
Proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs	19,153	63,108
Payment of contingent consideration	—	(1,063)
Net cash provided by financing activities	\$ 4,024	\$ 53,467
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	\$ (7,138)	\$ 10,218
<b>Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</b>	<b>(13,257)</b>	<b>113,157</b>
Cash, cash equivalents, and restricted cash at the beginning of period	250,077	153,115
<b>Cash, cash equivalents, and restricted cash at the end of period</b>	<b>\$ 236,820</b>	<b>\$ 266,272</b>
<b>Supplemental disclosures of cash flow information</b>		
Cash paid during the period for interest	\$ 47,587	\$ 35,448
Cash paid for taxes	\$ 2,729	\$ 6,473
Tenant improvements paid through lease incentives	\$ 217	\$ —
Capital expenditures unpaid at the end of period	\$ 168	\$ 877

*See accompanying Notes to Consolidated Financial Statements*

**Amicus Therapeutics, Inc.**  
**Notes to the Consolidated Financial Statements**  
*(Unaudited)*

## **1. Description of Business**

Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company seeks to deliver the highest quality therapies that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. The Company's two marketed therapies are Galafold<sup>®</sup>, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>, a novel two-component treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease.

Galafold<sup>®</sup> (also referred to as "migalastat"), is approved in over 40 countries around the world, including the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan. Additionally, Galafold<sup>®</sup> has been granted orphan drug status in the U.S., E.U., U.K., Japan and several other countries.

Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> (also referred to as "cipaglucosidase alfa-atga/miglustat"), is approved in the U.S., the E.U., the U.K., and Switzerland. Multiple regulatory submissions and reimbursement processes with global health authorities are currently underway. Additionally, Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> has been granted orphan drug designation or status in the U.S., U.K., Switzerland, and Japan and data exclusivity in the E.U.

The Company had an accumulated deficit of \$2.8 billion as of September 30, 2024 and anticipates incurring losses through the fiscal year ending December 31, 2024. The Company has historically funded its operations through stock offerings, product revenues, debt issuances, collaborations, and other financing arrangements.

Based on its current operating model, which includes expected revenues, the Company believes the current cash position is sufficient to fund the Company's operations and ongoing research programs for at least the next 12 months. Potential business development opportunities, pipeline expansion, and investment in manufacturing capabilities could impact the Company's long-term capital requirements.

## **2. Summary of Significant Accounting Policies**

### ***Basis of Presentation***

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, certain financial information that is normally included in annual financial statements prepared in accordance with U.S. GAAP, but that is not required for interim reporting purposes, has been omitted. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information. Management has determined that the Company operates in one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. For a complete description of the Company's accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

### ***Consolidation***

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.

### ***Foreign Currency Transactions***

The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the weighted average foreign exchange rates for the

period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity. Transactions which are not in the functional currency of the entity are remeasured into the functional currency with gains or losses resulting from the remeasurement recorded in other expense.

#### ***Use of Estimates***

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

#### ***Cash, Cash Equivalents, Marketable Securities, and Restricted Cash***

The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive income (loss) in the Company's Consolidated Statements of Comprehensive Income (Loss). Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.

Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included as a component of other non-current assets on the Company's Consolidated Balance Sheets.

#### ***Concentration of Credit Risk***

The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable.

The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.

The Company's accounts receivable at September 30, 2024 have primarily arisen from Galafold<sup>®</sup> sales in Europe, the U.S., and Japan. The Company periodically assesses the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of September 30, 2024, the Company's allowance for doubtful accounts was \$0.5 million.

#### ***Revenue Recognition***

The Company has recorded revenue on sales where its products are available either on a commercial basis or through a reimbursed early access program. Product orders are generally received from distributors and pharmacies.

The Company recognizes revenue when its performance obligation to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of the products. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which primarily consist of third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

The following table summarizes the Company's net product sales disaggregated by product:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Galafold®	\$ 120,381	\$ 100,733	\$ 330,557	\$ 281,177
Pombiliti® + Opfolda®	21,136	2,768	48,032	3,097
Total net product sales	\$ 141,517	\$ 103,501	\$ 378,589	\$ 284,274

The following table summarizes the Company's net product sales disaggregated by geographic area:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
U.S.	\$ 56,192	\$ 37,801	\$ 143,705	\$ 103,760
Ex-U.S.	85,325	65,700	234,884	180,514
Total net product sales	\$ 141,517	\$ 103,501	\$ 378,589	\$ 284,274

#### ***Inventories and Cost of Goods Sold***

Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Company's Consolidated Statements of Operations.

Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. A portion of Pombiliti® + Opfolda® inventory was expensed as research and development costs prior to regulatory approval and as such, the cost of goods sold and related gross margins are not necessarily indicative of future costs of goods sold and gross margin.

#### ***Recent Accounting Developments - Guidance Adopted in 2024***

In November 2023, the Financial Accounting Standards Board ("FASB") issued the Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): *Improvements to Reportable Segment Disclosures*. The amendments expand reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments require, among other things, disclosure of the title and position of the chief operating decision maker and require that public entities with a single reportable segment provide all disclosures required by this update and existing segment disclosures in Topic 280. Annual disclosures are required for fiscal years beginning after December 15, 2023 and interim disclosures are required for periods within fiscal years beginning after December 15, 2024. Retrospective application is required unless it is impracticable, and early adoption is permitted. The Company adopted this guidance on January 1, 2024. This ASU applies to disclosure requirements only, and the Company will provide required annual disclosures as part of the 2024 Annual Report on Form 10-K and required interim disclosures as part of 2025 Quarterly Reports on Form 10-Q.

#### ***Recent Accounting Developments - Guidance Not Yet Adopted***

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): *Improvements to Income Tax Disclosures*. The ASU requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, must be applied prospectively with an option to apply retrospectively, and early adoption is permitted. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements. The Company is currently assessing the impact this standard will have on its consolidated financial statements.

### **3. Cash, Cash Equivalents, Marketable Securities, and Restricted Cash**

As of September 30, 2024, the Company held \$233.6 million in cash and cash equivalents and \$16.1 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive income (loss) in the Consolidated Statements of Comprehensive Income (Loss). If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security's fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in the Consolidated Statements of Operations as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss, the Company would recognize an allowance and the corresponding credit loss would be included in the Consolidated Statements of Operations.

The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as, in accordance with Company policy, such securities are of high credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.

Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:

(in thousands)	As of September 30, 2024			
	Cost	Gross Unrealized Gain	Gross Unrealized Loss	Fair Value
Cash and cash equivalents	\$ 233,647	\$ —	\$ —	\$ 233,647
Commercial paper	5,991	—	—	5,991
Treasury bill	9,958	10	—	9,968
U.S. government agency bonds	—	—	—	—
Money market	100	—	—	100
Certificates of deposit	51	—	—	51
	<u>\$ 249,747</u>	<u>\$ 10</u>	<u>\$ —</u>	<u>\$ 249,757</u>
Included in cash and cash equivalents	\$ 233,647	\$ —	\$ —	\$ 233,647
Included in marketable securities	16,100	10	—	16,110
Total cash, cash equivalents, and marketable securities	<u>\$ 249,747</u>	<u>\$ 10</u>	<u>\$ —</u>	<u>\$ 249,757</u>

(in thousands)	As of December 31, 2023			
	Cost	Gross Unrealized Gain	Gross Unrealized Loss	Fair Value
Cash and cash equivalents	\$ 246,994	\$ —	\$ —	\$ 246,994
Commercial paper	14,651	12	—	14,663
Treasury bill	12,944	2	—	12,946
U.S. government agency bonds	11,450	—	(4)	11,446
Money market	100	—	—	100
Certificate of deposit	51	—	—	51
	<u>\$ 286,190</u>	<u>\$ 14</u>	<u>\$ (4)</u>	<u>\$ 286,200</u>
Included in cash and cash equivalents	\$ 246,994	\$ —	\$ —	\$ 246,994
Included in marketable securities	39,196	14	(4)	39,206
Total cash, cash equivalents, and marketable securities	<u>\$ 286,190</u>	<u>\$ 14</u>	<u>\$ (4)</u>	<u>\$ 286,200</u>

For both the nine months ended September 30, 2024 and September 30, 2023, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.

There were no unrealized loss positions as of September 30, 2024. Unrealized loss positions in the marketable securities as of December 31, 2023 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized as a component of other comprehensive income (loss). The fair value of these marketable securities in unrealized loss positions are \$0.0 million and \$11.4 million as of September 30, 2024 and December 31, 2023, respectively.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total shown in the Consolidated Statements of Cash Flows.

(in thousands)	As of September 30,	
	2024	2023
Cash and cash equivalents	\$ 233,647	\$ 263,320
Restricted cash	3,173	2,952
Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows	<u>\$ 236,820</u>	<u>\$ 266,272</u>

#### 4. Inventories

The following table summarizes the components of the Company's inventories for each of the periods indicated:

(in thousands)	September 30, 2024	December 31, 2023
Raw materials	\$ 76,203	\$ 30,230
Work-in-process	31,485	22,597
Finished goods	7,650	6,869
Total inventories	<u>\$ 115,338</u>	<u>\$ 59,696</u>

The Company's reserve for inventory was \$3.5 million and \$0.5 million as of September 30, 2024 and December 31, 2023, respectively.

#### 5. Debt

The following table summarizes the Company's debt for each of the periods indicated:

(in thousands)	September 30, 2024	December 31, 2023
<b>Senior Secured Term Loan due 2029:</b>		
Principal	\$ 400,000	\$ 400,000
Less: debt discount <sup>(1)</sup>	(8,339)	(9,650)
Less: deferred financing <sup>(1)</sup>	(2,167)	(2,450)
Net carrying value of long-term debt	<u>\$ 389,494</u>	<u>\$ 387,890</u>

<sup>(1)</sup> Included in the Company's Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2029 using the effective interest rate method.

#### *Interest Expense*

The following table sets forth interest expense recognized related to the Company's debt for the three and nine months ended September 30, 2024 and 2023, respectively:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Contractual interest expense	\$ 12,106	\$ 12,270	\$ 36,021	\$ 35,200
Amortization of debt discount	\$ 455	\$ 411	\$ 1,313	\$ 1,100
Amortization of deferred financing	\$ 119	\$ 310	\$ 352	\$ 800

#### 6. Restructuring

The restructuring liabilities are recorded in accrued expenses and other current liabilities in the Company's Consolidated Balance Sheets. Total charges incurred are summarized as follows:

(in thousands)	Facility and Non-Lease Costs	Other Costs	Total
<b>Balance as of December 31, 2023</b>	\$ —	\$ —	\$ —
Restructuring charges	6,045	3,143	9,188
Non-cash items	(2,844)	—	(2,844)
Cash settled	(981)	(2,136)	(3,117)
<b>Balance as of September 30, 2024</b>	<u>\$ 2,220</u>	<u>\$ 1,007</u>	<u>\$ 3,227</u>

#### 7. Stockholders' Equity

During the three and nine months ended September 30, 2024, the Company issued and sold an aggregate of 1,692,291 shares through its at-the-market equity program ("ATM program") at weighted-average public offering price of \$11.70 per share, resulting in net proceeds of \$19.2 million. As of September 30, 2024, an aggregate of \$164.7 million worth of shares remain available to be issued and sold under the ATM program.

## 8. Stock-Based Compensation

The Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.

### Stock Option Grants

The fair value of the stock options granted were estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Expected stock price volatility	55.5 %	58.4 %	57.1 %	59.2
Risk free interest rate	3.9 %	4.3 %	4.0 %	3.9
Expected life of options (years)	5.6	5.5	5.6	
Expected annual dividend per share	\$ —	\$ —	\$ —	\$ —

A summary of the Company's stock options for the nine months ended September 30, 2024 were as follows:

	Number of Shares (in thousands)	Weighted Average Exercise Price	Weighted Average Remaining Years	Aggregate Intrinsic Value (in millions)
Options outstanding, December 31, 2023	23,002	\$ 11.69		
Granted	4,693	\$ 13.69		
Exercised	(791)	\$ 7.74		
Forfeited	(548)	\$ 12.74		
Expired	(217)	\$ 14.58		
Options outstanding, September 30, 2024	26,139	\$ 12.12	6.0	\$ 13
Vested and non-vested expected to vest, September 30, 2024	24,610	\$ 12.09	5.9	\$ 13
Exercisable at September 30, 2024	17,092	\$ 11.75	4.7	\$ 13

As of September 30, 2024, the total unrecognized compensation cost related to non-vested stock options granted was \$43.4 million and is expected to be recognized over a weighted average period of three years.

*Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")*

RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2024 is as follows:

	Number of Shares (in thousands)	Weighted Average Grant Date Fair Value	Weighted Average Remaining Years	Aggregate Intrinsic Value (in millions)
Non-vested units as of December 31, 2023	10,033	\$ 13.37		
Granted	3,893	\$ 14.63		
Vested	(3,860)	\$ 13.17		
Forfeited	(613)	\$ 14.28		
Non-vested units as of September 30, 2024	<u>9,453</u>	<u>\$ 13.82</u>	2.2	\$ 101

As of September 30, 2024, there was \$62.8 million of total unrecognized compensation cost related to non-vested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.

*Compensation Expense Related to Equity Awards*

The following table summarizes information related to compensation expense recognized in the Company's Consolidated Statements of Operations related to the equity awards:

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Research and development expense	\$ 4,397	\$ 4,380	\$ 12,329	\$ 16,9
Selling, general, and administrative expense	14,291	12,131	53,359	50,9
Total equity compensation expense	<u>\$ 18,688</u>	<u>\$ 16,511</u>	<u>\$ 65,688</u>	<u>\$ 67,9</u>

**9. Assets and Liabilities Measured at Fair Value**

The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:

*Level 1* — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

*Level 2* — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.

*Level 3* — Inputs that are unobservable for the asset or liability.

A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2024 are identified in the following tables:

(in thousands)	Level 1	Level 2	Total
<b>Assets:</b>			
Commercial paper	\$ —	\$ 5,991	\$ 5,991
Treasury bill	—	9,968	9,968
Money market	7,922	—	7,922
	<u>\$ 7,922</u>	<u>\$ 15,959</u>	<u>\$ 23,881</u>

(in thousands)	Level 1	Level 2	Total
<b>Liabilities:</b>			
Deferred compensation plan liability	\$ 7,822	\$ —	\$ 7,822
	<u>\$ 7,822</u>	<u>\$ —</u>	<u>\$ 7,822</u>

A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2023 are identified in the following tables:

(in thousands)	Level 1	Level 2	Total
<b>Assets:</b>			
Commercial paper	\$ —	\$ 14,663	\$ 14,663
Treasury bill	—	12,946	12,946
U.S. government agency bonds	—	11,446	11,446
Money market	7,631	—	7,631
	<u>\$ 7,631</u>	<u>\$ 39,055</u>	<u>\$ 46,686</u>

(in thousands)	Level 1	Level 2	Total
<b>Liabilities:</b>			
Deferred compensation plan liability	7,531	—	7,531
	<u>\$ 7,531</u>	<u>\$ —</u>	<u>\$ 7,531</u>

Deferred compensation plan liability is recorded as a component of other non-current liabilities on the Company's Consolidated Balance Sheets. The Company did not have any Level 3 assets or liabilities as of September 30, 2024 or December 31, 2023.

#### **Cash, Money Market Funds, and Marketable Securities**

The Company classifies its cash and money market funds within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities.

## 10. Basic and Diluted Net Loss per Common Share

The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:

(in thousands, except per share amounts)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Net loss attributable to common stockholders	\$ (6,729)	\$ (21,577)	\$ (70,845)	\$ (117,771)
Denominator:				
Weighted average common shares outstanding — basic and diluted	304,690,596	295,759,435	303,792,479	293,314,111

Dilutive common stock equivalents would include the dilutive effect of outstanding common stock options and non-vested RSUs. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. Weighted average common shares outstanding includes outstanding pre-funded warrants with an exercise price of \$0.01.

The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:

(in thousands)	As of September 30,	
	2024	2023
Options to purchase common stock	26,139	23,211
Non-vested restricted stock units	9,453	10,311
Total number of potentially issuable shares	35,592	33,522

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Some of the statements we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section in this Quarterly Report on Form 10-Q entitled "Special Note Regarding Forward-Looking Statements". Certain risk factors may cause actual results, performance or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see the section in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 entitled "Risk Factors".

### Overview

We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We seek to deliver the highest quality therapies that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. Our two marketed therapies are Galafold<sup>®</sup>, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti<sup>®</sup> + Opfolda<sup>®</sup>, a novel two-component treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease.

Galafold<sup>®</sup> (also referred to as "migalastat") is approved in over 40 countries around the world, including the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan. Additionally, Galafold<sup>®</sup> has been granted orphan drug status in the U.S., E.U., U.K., Japan and several other countries.

Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> (also referred to as "cipaglucosidase alfa-atga/miglustat") is approved in the U.S., the E.U., the U.K., and Switzerland. Multiple regulatory submissions and reimbursement processes with global health authorities are currently underway. Additionally, Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> has been granted orphan drug designation or status in the U.S., U.K., Switzerland and Japan and data exclusivity in the E.U.

### Our Strategy

Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare diseases through internally developed, jointly developed, acquired, or in-licensed products and product candidates. We are leveraging our global capabilities to develop and broaden our franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel technologies.

Highlights of our progress include:

- *Commercial success in Fabry disease.* For the nine months ended September 30, 2024, Galafold<sup>®</sup> revenue was \$330.6 million of consolidated revenue, which represented an increase of \$49.4 million compared the same period in the prior year. We continue to see strong commercial momentum and expansion into additional geographies.
- *Commercial and regulatory success in Pompe disease.* For the nine months ended September 30, 2024, Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> revenue was \$48.0 million of consolidated revenue. Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> was approved by the European Commission ("EC") in June 2023, the Medicines and Healthcare products Regulatory Agency ("MHRA") of the United Kingdom in August 2023, the U.S. Food and Drug Administration ("FDA") in September 2023, and the Swissmedic of Switzerland in July 2024.
- *Pipeline advancement and growth.* We are leveraging our global capabilities to develop and broaden our franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel technologies.
- *Financial strength.* Total cash, cash equivalents, and marketable securities as of September 30, 2024 was \$249.8 million.

## **Our Commercial Products and Product Candidates**

### ***Galafold® (migalastat HCl) for Fabry Disease***

Our oral precision medicine, Galafold®, was granted accelerated approval by the FDA in August 2018 for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. Galafold® was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable variant. Marketing authorization approvals as well as approvals for adolescents aged 12 years and older weighing 45 kg or more have been granted in over 40 countries around the world. We plan to continue to launch Galafold® in additional countries upon receipt of marketing authorization.

As an orally administered monotherapy, Galafold® is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice ("GLP") cell-based amenability assay.

### ***Pombiliti® (cipaglusosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease***

We have leveraged our biologics capabilities to develop Pombiliti® + Opfolda®, a novel treatment paradigm for Pompe disease. Pombiliti® + Opfolda® was approved by the EC in June 2023, the MHRA in August 2023, the FDA in September 2023, and the Swissmedic in July 2024 for adult late-onset Pompe disease ("LOPD") patients. Additional regulatory submissions and reimbursement processes with global health authorities are currently underway.

Pombiliti® + Opfolda® consists of a uniquely engineered rhGAA enzyme, cipaglusosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. Miglustat binds to and stabilizes the cipaglusosidase alfa-atga in circulation reducing inactivation of rhGAA to improve the uptake of active enzyme into key disease relevant tissues. Miglustat is not an active ingredient that contributes directly to glycogen reduction.

In addition, clinical studies are ongoing in pediatric patients for both the LOPD and infantile-onset Pompe disease ("IOPD") populations.

### ***Next Generation Therapies***

We are committed to continued innovation for all people living with Fabry or Pompe disease. As part of our long-term commitment, we are continuing discovery efforts for next-generation genetic medicines for Fabry and Pompe disease.

### ***Strategic Alliances and Arrangements***

We will continue to evaluate business development opportunities to build stockholder value and provide us with access to the financial, technical, clinical, commercial resources, and intellectual property necessary to develop and market technologies or products in rare and orphan diseases. We are exploring potential collaborations, alliances, and various other business development opportunities on a regular basis. These opportunities may include business combinations, partnerships, the strategic out-licensing of certain assets, or the acquisition of preclinical-stage, clinical-stage, or marketed products or novel technologies consistent with our corporate strategy to develop and provide therapies to patients living with rare and orphan diseases.

## Consolidated Results of Operations

### Three Months Ended September 30, 2024 compared to September 30, 2023

The following table provides selected financial information for the Company:

(in thousands)	Three Months Ended September 30,		
	2024	2023	Change
Net product sales	\$ 141,517	\$ 103,501	\$ 38,016
Cost of goods sold	13,279	9,946	3,333
Cost of goods sold as a percentage of net product sales	9.4 %	9.6 %	(0.2)
Operating expenses:			
Research and development	26,160	40,704	(14,544)
Selling, general, and administrative	75,106	65,651	9,455
Changes in fair value of contingent consideration payable	—	1,995	(1,995)
Restructuring charges	3,143	—	3,143
Depreciation and amortization	2,170	2,228	(58)
Other expense:			
Interest income	1,081	1,471	(390)
Interest expense	(12,692)	(12,986)	294
Other (expense) income	(3,263)	3,833	(7,096)
Income tax (expense) benefit	(13,514)	3,128	(16,642)
Net loss attributable to common stockholders	\$ (6,729)	\$ (21,577)	\$ 14,848

*Net Product Sales.* Net product sales increased \$38.0 million during the three months ended September 30, 2024 compared to the same period in the prior year. The increase was primarily due to both the continued growth of Galafold® in Europe and the U.S. as well as the launch of Pombiliti® + Opfolda® in Europe and the U.S., and a \$0.8 million favorable impact of foreign currency exchange.

*Research and Development Expense.* The following table summarizes our principal development programs and the out-of-pocket, third-party expenses incurred:

(in thousands)	Three Months Ended September 30,	
	2024	2023
<b>Projects</b>		
Third party direct project expenses		
Galafold® (Fabry Disease)	\$ 2,380	\$ 4,505
Pombiliti® + Opfolda® (Pompe Disease)	10,590	15,233
Pre-clinical and other programs	646	1,753
Total third-party direct project expenses	13,616	21,491
Other project costs		
Personnel costs	9,707	15,194
Other costs	2,837	4,019
Total other project costs	12,544	19,213
Total research and development costs	\$ 26,160	\$ 40,704

The \$14.5 million decrease in research and development costs was primarily driven by our Pombiliti® + Opfolda® commercial launch, decreasing both clinical spend and the number of employees supporting research and development efforts.

*Selling, General, and Administrative Expense.* Selling, general, and administrative expense increased \$9.5 million, primarily driven by personnel costs resulting from an increase in the number of employees to support our commercial launch activities and third party professional fees.

*Other (Expense) Income.* The decrease of \$7.1 million was primarily related to movement in foreign exchange rates caused by remeasurement of foreign-denominated balances.

*Income Tax Expense.* We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the mix of pre-tax earnings among the many jurisdictions in which we operate and differences in the timing of the recognition of such earnings under the relevant accounting standards and tax rules.

### Consolidated Results of Operations

#### Nine Months Ended September 30, 2024 compared to September 30, 2023

The following table provides selected financial information for the Company:

(in thousands)	Nine Months Ended September 30,		
	2024	2023	Change
Net product sales	\$ 378,589	\$ 284,274	\$ 94,315
Cost of goods sold	38,107	26,002	12,105
Cost of goods sold as a percentage of net product sales	10.1 %	9.1 %	1.0
Operating expenses:			
Research and development	79,172	117,352	(38,180)
Selling, general, and administrative	236,711	205,031	31,680
Changes in fair value of contingent consideration payable	—	2,583	(2,583)
Restructuring charges	9,188	—	9,188
Loss on impairment of assets	—	1,134	(1,134)
Depreciation and amortization	6,506	5,691	815
Other expense:			
Interest income	3,991	5,407	(1,416)
Interest expense	(37,640)	(37,322)	(318)
Other expense	(11,946)	(13,007)	1,061
Income tax (expense) benefit	(34,155)	700	(34,855)
Net loss attributable to common stockholders	\$ (70,845)	\$ (117,741)	\$ 46,896

*Net Product Sales.* Net product sales increased \$94.3 million during the nine months ended September 30, 2024 compared to the same period in the prior year. The increase was primarily due to both the continued growth of Galafold® in Europe and the U.S. as well as the launch of Pombiliti® + Opfolda® in Europe and the U.S., partially offset by the \$0.9 million unfavorable impact of foreign currency exchange.

*Cost of goods sold.* Cost of goods sold includes manufacturing costs as well as royalties associated with net product sales. Cost of goods sold as a percentage of net product sales increased 1.0% primarily due to inventory write-offs associated with validation efforts in the current period.

*Research and Development Expense.* The following table summarizes our principal development programs and the out-of-pocket, third-party expenses incurred:

(in thousands)	Nine Months Ended September 30,	
<i>Projects</i>	2024	2023
Third party direct project expenses		
Galafold® (Fabry Disease)	\$ 6,420	\$ 10,971
Pombiliti® + Opfolda® (Pompe Disease)	31,003	44,126
Pre-clinical and other programs	2,095	3,218
Total third-party direct project expenses	39,518	58,315
Other project costs		
Personnel costs	31,287	47,108
Other costs	8,367	11,929
Total other project costs	39,654	59,037
Total research and development costs	\$ 79,172	\$ 117,352

The \$38.2 million decrease in research and development costs was primarily driven by our Pombiliti® + Opfolda® commercial launch, decreasing both clinical spend and the number of employees supporting research and development efforts.

*Selling, General, and Administrative Expense.* Selling, general, and administrative expense increased \$31.7 million, primarily driven by personnel costs resulting from an increase in the number of employees to support our commercial launch activities, external costs required to support the manufacture and sale of our commercial products, and third-party professional fees.

*Restructuring Charges.* Restructuring charges were primarily related to an initiative to reduce operating costs by abandoning a lease that we no longer believe is useful in our operations.

*Income Tax Expense.* We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the mix of pre-tax earnings among the many jurisdictions in which we operate and differences in the timing of the recognition of such earnings under the relevant accounting standards and tax rules.

## Liquidity and Capital Resources

As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold® and Pombiliti® + Opfolda®, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, product revenues, debt issuance, collaborations, and other financing arrangements.

### Sources of Liquidity

In November 2022, we entered into a Sales Agreement with Goldman Sachs & Co. LLC to create an at-the-market equity program ("ATM program"), pursuant to which we may offer to sell shares of our common stock having an aggregate offering gross proceeds of up to \$250.0 million. As of September 30, 2024, an aggregate of \$164.7 million worth of shares remain available to be issued and sold under the ATM program.

### ***Cash Flow Discussion***

As of September 30, 2024, we had cash, cash equivalents, and marketable securities of \$249.8 million. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "— Note 3. Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.

#### ***Net Cash Used in Operating Activities***

Net cash used in operations for the nine months ended September 30, 2024 was \$30.0 million. The components of net cash used in operations included the net loss for the nine months ended September 30, 2024 of \$70.8 million and a net decrease in changes in operating assets and liabilities of \$55.2 million offset by \$65.7 million of stock compensation and \$30.4 million of other non-cash adjustments. The changes in operating assets and liabilities were primarily due to an increase in inventory of \$61.6 million to support our continued commercial growth and an increase in accounts receivable of \$9.1 million, partially offset by a decrease in prepaid expenses and other current assets of \$28.2 million and a decrease in accounts payable and accrued expenses of \$11.5 million associated with timing of payments.

Net cash used in operations for the nine months ended September 30, 2023 was \$72.5 million. The components of net cash used in operations included the net loss for the nine months ended September 30, 2023 of \$117.7 million offset by \$68.0 million of stock compensation, \$25.9 million of other non-cash adjustments, and a net increase in changes in operating assets and liabilities of \$48.7 million. The changes in operating assets and liabilities were primarily due to an increase in inventory of \$42.2 million and an increase in prepaid expenses and other current assets of \$26.0 million, partially offset by an increase in accounts payable and accrued expenses of \$41.1 million associated with Pombiliti<sup>®</sup> + Opfolda<sup>®</sup> launch activities and increases in sales rebates associated with increased commercial sales of Galafold<sup>®</sup>.

#### ***Net Cash Provided by Investing Activities***

Net cash provided by investing activities for the nine months ended September 30, 2024 was \$19.8 million. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash provided by investing activities reflects \$101.9 million from the sale and redemption of marketable securities, partially offset by \$78.8 million for the purchase of marketable securities and \$3.3 million for capital expenditures.

Net cash provided by investing activities for the nine months ended September 30, 2023 was \$122.0 million. Our investing activities have consisted primarily of purchases, sales and maturities of investments and capital expenditures. Net cash provided by investing activities reflects \$180.8 million from the sale and redemption of marketable securities, partially offset by \$53.1 million for the purchase of marketable securities and \$5.7 million for capital expenditures.

#### ***Net Cash Provided by Financing Activities***

Net cash provided by financing activities for the nine months ended September 30, 2024 was \$4.0 million. Net cash provided by financing activities primarily reflects \$19.2 million of proceeds from the issuance of shares in connection with the ATM program offering, net of issuance costs, and \$6.1 million of proceeds from the exercise of stock options, partially offset by the withholding taxes paid on vested restricted stock units of \$21.2 million.

Net cash provided by financing activities for the nine months ended September 30, 2023 was \$53.5 million. Net cash provided by financing activities primarily reflects \$63.1 million of proceeds from the issuance of shares in connection with the ATM program offering, net of issuance costs, and \$7.8 million of proceeds from the exercise of stock options, partially offset by the withholding taxes paid on vested restricted stock units of \$16.4 million.

## Funding Requirements

We expect to continue to incur significant costs in the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials. Our future capital requirements will depend on a number of factors, including:

- the scope, progress, results and costs of clinical trials for our drug candidates;
- the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pombiliti® (also referred to as "ATB200" or "cipaglicosidase alfa");
- the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize such therapies;
- the costs, timing, and outcome of regulatory review of our product candidates;
- any changes in regulatory standards relating to the review of our product candidates;
- any changes in laws, rules or regulations affecting our ability to manufacture, transport, test, develop, or commercialize our products, including Galafold®, Pombiliti® + Opfolda®, or our product candidates;
- the costs of commercialization activities, including product marketing, sales, and distribution;
- the emergence of competing technologies and other adverse market developments;
- the estimates regarding the potential market opportunity for our products and product candidates;
- our ability to successfully commercialize Galafold® (also referred to as "migalastat HCl");
- our ability to successfully commercialize Pombiliti® + Opfolda® (together, also referred to as "AT-GAA") in the E.U., U.K., and U.S., Switzerland and elsewhere, if regulatory applications are approved;
- our ability to manufacture or supply sufficient clinical or commercial products, including Galafold® and Pombiliti® + Opfolda®;
- our ability to obtain reimbursement for Galafold® and Pombiliti® + Opfolda®;
- our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold® and Pombiliti® + Opfolda®;
- our ability to obtain market acceptance of Galafold® and Pombiliti® + Opfolda® or any other product developed or acquired that has received regulatory approval;
- the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;
- the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others, including Hatch-Waxman litigation;
- the extent to which we acquire or invest in businesses, products, and technologies;
- our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;
- our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other economic benefits from any such collaborators;
- the costs associated with, and our ability to comply with, emerging environmental, social and governance standards, including climate reporting requirements at the local, state and national levels;
- our ability to successfully protect our information technology systems and maintain our global operations and supply chain without interruption;
- our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;
- fluctuations in foreign currency exchange rates; and
- changes in accounting standards.

We may seek additional funding through public or private financings of debt or equity. Based on our current operating model, which includes expected revenues, we believe that the current cash position is sufficient to fund our operations and ongoing research programs for at least the next 12 months. Potential impacts of business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our long-term capital requirements.

### **Critical Accounting Policies and Significant Judgments**

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments and make changes when necessary. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There were no significant changes during the nine months ended September 30, 2024 to the items that we disclosed as our significant accounting policies and estimates described in "—Note 2. Summary of Significant Accounting Policies" to the Company's financial statements as contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

### ***Recent Accounting Pronouncements***

Please refer to "—Note 2. Summary of Significant Accounting Policies" in our Notes to Consolidated Financial Statements.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. As of September 30, 2024, there have been no material changes to our market risks or to our management of such risks since December 31, 2023.

### **ITEM 4. CONTROLS AND PROCEDURES**

#### **Evaluation of Disclosure Controls and Procedures**

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation of the effectiveness of our disclosure controls and procedures (pursuant to Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") was carried out under the supervision of our Principal Executive Officer and Principal Financial Officer, with the participation of our management. Based on that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

During the fiscal quarter covered by this report, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

In the fourth quarter of 2022, the Company received Paragraph IV Certification Notice Letters from Teva Pharmaceuticals USA, Inc. ("Teva"), Aurobindo Pharma Limited ("Aurobindo"), and Lupin Limited ("Lupin") in connection with Abbreviated New Drug Applications ("ANDA") filed with the FDA requesting approval to market generic Galafold®. In November 2022, the Company filed four lawsuits against Teva, Lupin, and Aurobindo in the U.S. District Court for the District of Delaware (the "Court") for infringement of its Orange Book-listed patents. In the fourth quarter of 2023, a stipulation order to stay litigation with respect to Lupin was ordered. Additionally, in the first quarter of 2024, a stipulation was filed with the court and approved by the presiding judge, whereby the parties agreed to accept the Company's definition of the terms that were in dispute. As such, the scheduled Markman hearing was deemed unneeded and cancelled.

In October 2024, the Company entered into a non-exclusive, non-transferable, royalty-free, fully paid-up license with Teva which will allow Teva to market its generic version of Galafold® in the United States beginning on January 30, 2037, or earlier in certain circumstances. In accordance with the license agreement, a consent judgment and permanent injunction was entered with the Court and all Hatch-Waxman litigation between Amicus and Teva has been terminated. As required by law, Amicus and Teva have submitted the confidential license agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.

The litigation will continue against Aurobindo as the remaining active party, and the litigation stay remains in place for Lupin. The Company has, and will continue to, vigorously enforce its Galafold® intellectual property rights.

### **ITEM 1A. RISK FACTORS**

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

### **ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

#### **Recent Sales of Unregistered Securities**

None.

## Issuer Purchases of Equity Securities

The following table provides certain information with respect to purchase of our common stock during the three months ended September 30, 2024:

Period	Total Number of Shares Purchased <sup>(1)</sup>	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs
July 1, 2024 through July 31, 2024	92,738	\$ 10.59	—	—
August 1, 2024 through August 31, 2024	23,287	\$ 11.80	—	—
September 1, 2024 through September 30, 2024	127,806	\$ 11.60	—	—
Total	243,831	\$ 11.23	—	—

<sup>(1)</sup> Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock units

## ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

## ITEM 4. MINE SAFETY DISCLOSURES

None.

## ITEM 5. OTHER INFORMATION

### Rule 10b5-1 Trading Plans

The following table describes, for the quarterly period covered by this report, each director and officer (as defined in Rule 16a-1(f) under the Exchange Act who has adopted, modified, or terminated a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act (each plan, a “Rule 10b5-1 Trading Plan”). Each Rule 10b5-1 Trading Plan described below was adopted during an open insider trading window and in accordance with the Company’s policies regarding both insider trading and transactions relating to Company securities.

Name (Title)	Action Taken (Date of Action)	Rule 10b5-1 Trading Plan Provides for Purchase/Sale	Duration of the Trading Plan <sup>(1)</sup>	Aggregate Number of Securities
Bradley Campbell (President and Chief Executive Officer)	Adoption (September 13, 2024)	Sale	December 31, 2025	235,460 <sup>(2)</sup>
Jeffrey Castelli (Chief Development Officer)	Adoption (September 10, 2024)	Sale	May 31, 2025	132,954 <sup>(3)</sup>
David Clark (Chief People Officer)	Adoption (August 28, 2024)	Sale	August 15, 2025	Indeterminable <sup>(4)</sup>
Samantha Prout (Chief Accounting Officer)	Adoption (September 12, 2024)	Sale	July 1, 2025	Indeterminable <sup>(5)</sup>
Ellen Rosenberg (Chief Legal Officer and Corporate Secretary)	Adoption (September 10, 2024)	Sale	December 31, 2025	95,621 <sup>(6)</sup>

<sup>(1)</sup> The dates in this column represent the scheduled expiration date of each director or officer’s Rule 10b5-1 Trading Plan. Each Rule 10b5-1 Trading Plan may terminate earlier than the date provided should all transactions contemplated thereunder occur prior to such date.

<sup>(2)</sup> Mr. Campbell’s Rule 10b5-1 Trading Plan provides for the (i) sale of 60,460 shares of common stock and (ii) exercise of up to 175,000 stock options and subsequent sale of up to 175,000 shares of common stock underlying such stock options.

<sup>(3)</sup> Mr. Castelli’s Rule 10b5-1 Trading Plan provides for the (i) sale of 82,954 shares of common stock and (ii) exercise of up to 50,000 stock options and subsequent sale of up to 50,000 shares of common stock underlying such stock options.

<sup>(4)</sup> Mr. Clark's Rule 10b5-1 Trading Plan provides for the sale of common stock that will be obtained from the settlement of his 2022 PRSU awards and the respective vesting of his 2021, 2022, 2023 and 2024 annual restricted stock unit awards. The number of shares of common stock obtained and available for sale will be subject to the (i) level of achievement of each performance goal contained within the 2022 PRSU awards and (ii) shares of common stock withheld to satisfy applicable tax withholding obligations.

<sup>(5)</sup> Ms. Prout's Rule 10b5-1 Trading Plan provides for the (i) exercise of up to 66,074 stock options and the sale of up to 66,074 underlying shares of common stock, (ii) sale of 7,243 shares of common stock and (iii) sale of an indeterminable number of shares of common stock to be obtained from the respective vesting of her 2021, 2022, 2023 and 2024 annual restricted stock unit awards. The number of shares of common stock obtained and available for sale in clause (iii) will be subject to the shares of common stock withheld to satisfy applicable tax withholding obligations.

<sup>(6)</sup> Ms. Rosenberg's Rule 10b5-1 Trading Plan provides for the exercise of up to 95,621 stock options and the sale of up to 95,621 underlying shares of common stock.

**ITEM 6. EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
31.1	<a href="#"><u>Certification of Principal Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</u></a>
31.2	<a href="#"><u>Certification of Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</u></a>
32.1	<a href="#"><u>Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
104	Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)



**CERTIFICATIONS PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002  
CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER**

I, Bradley L. Campbell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amicus Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2024

\_\_\_\_\_  
/s/ Bradley L. Campbell  
Bradley L. Campbell  
**President and Chief Executive Officer**

**CERTIFICATIONS PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002  
CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER**

I, Simon Harford, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amicus Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2024

/s/ Simon Harford  
\_\_\_\_\_  
Simon Harford  
**Chief Financial Officer**

